<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4078502E-4611-49D3-8E8A-05B4F529EA45"><gtr:id>4078502E-4611-49D3-8E8A-05B4F529EA45</gtr:id><gtr:firstName>Hanh</gtr:firstName><gtr:surname>Doan Thi Hong</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/17AE4AF5-F4C8-478C-90E5-CC519CBE463E"><gtr:id>17AE4AF5-F4C8-478C-90E5-CC519CBE463E</gtr:id><gtr:firstName>Cuong</gtr:firstName><gtr:surname>Do Duy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/87E8E0FF-93EF-4131-A389-4687F8D466CB"><gtr:id>87E8E0FF-93EF-4131-A389-4687F8D466CB</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Horby</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B6B9BBF4-BE38-40E2-AE0B-AAEE2E5B04EA"><gtr:id>B6B9BBF4-BE38-40E2-AE0B-AAEE2E5B04EA</gtr:id><gtr:firstName>Marcel</gtr:firstName><gtr:surname>Wolbers</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/61A12C6D-128A-4EB3-A211-4193E6A2CEA8"><gtr:id>61A12C6D-128A-4EB3-A211-4193E6A2CEA8</gtr:id><gtr:firstName>Mattias</gtr:firstName><gtr:surname>Larsson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D1C5947D-8FD1-4F79-A0C9-C0432A8D2B38"><gtr:id>D1C5947D-8FD1-4F79-A0C9-C0432A8D2B38</gtr:id><gtr:firstName>Alastair</gtr:firstName><gtr:otherNames>McIntosh</gtr:otherNames><gtr:surname>Gray</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/85D780C7-1091-4550-A5C1-208E49F7644B"><gtr:id>85D780C7-1091-4550-A5C1-208E49F7644B</gtr:id><gtr:firstName>Chi H</gtr:firstName><gtr:surname>Nguyen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/08A7725D-D312-4AA2-BB7F-8287EF8A1589"><gtr:id>08A7725D-D312-4AA2-BB7F-8287EF8A1589</gtr:id><gtr:firstName>Kinh</gtr:firstName><gtr:surname>Nguyen Van</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0180270E-4D27-4B1D-838E-7C64B46D9D1E"><gtr:id>0180270E-4D27-4B1D-838E-7C64B46D9D1E</gtr:id><gtr:firstName>Thuy</gtr:firstName><gtr:surname>Le</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D58D9098-CD92-436D-909F-5908069FC028"><gtr:id>D58D9098-CD92-436D-909F-5908069FC028</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:surname>Farrar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1100682"><gtr:id>50AA99BD-6E93-4CAB-A2E7-F688251E0CAD</gtr:id><gtr:title>A Randomised, Open-Label, Comparative Study of Itraconazole vs. Amphotericin B for the Induction Therapy of Penicilliosi</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100682</gtr:grantReference><gtr:abstractText>Penicilliosis is one of the most common and life-threatening infections in people infected with Human Immunodeficiency Virus (HIV) in Asia. Despite the fast growing numbers of people infected with HIV in Asia where over one half of the world?s population lives, there has not been any clinical trials to evaluate the treatment of penicilliosis. The current international guideline recommends treatment with amphotericin B for 2 weeks followed by itraconazole for 10 weeks. This guideline is based on one observational study without a comparator group and is generally considered weak evidence in medicine. Further, amphotericin B is either unavailable or available in only selected major tertiary care centres in Asia, can only be given through a vein daily over 6 hours of infusion, has many side effects, and a 2 week treatment in Viet Nam for example would cost an average patient approximately 5 times his monthly salary . Itraconazole, on the other hand, appears to be a good alternative drug that is widely available in local pharmacies in the provinces and district clinics, can be given by mouth, is generally well tolerated, and costs a fraction of the price of amphotericin B. Available data from Viet Nam, Thailand, Hong Kong and India suggest that itraconazole may have similar treatment efficacy compared to amphotericin B. Therefore we will conduct a clinical trial comparing the relative effectiveness of itraconazole versus amphotericin in the treatment of penicilliosis. A total of 440 adults who are diagnosed with penicilliosis will be invited to participate in the study and will be randomly assigned to either itraconazole or amphotericin B during the first 2 week of therapy. Survival rates will be compared in the 2 treatment arms at the end of 2 weeks and in 6 months. This will be the landmark study for treatment of penicilliosis. The results will either change or support the current national and international guidelines for treatment of penicilliosis. If the investigators are correct, that itraconazole is proven to be at least as effective as amphotericin B, but is much cheaper, better tolerated, and easier to administer, then itraconazole represents a better treatment choice for the patients with penicilliosis while saving significant costs for the patients and the health care system. If the investigators are correct, then itraconazole can be given immediately for patients in the local provincial and district clinics, ensuring earlier treatment and better outcomes for patients.</gtr:abstractText><gtr:technicalSummary>Penicilliosis is emerging as one of the three most common HIV-associated opportunistic infections in Asia. Despite the rapid growing HIV epidemics in a region that houses one half of the worlds population, there has not been a single randomised controlled trial to evaluate the treatment of penicilliosis. The current recommendation of amphotericin B for 2 weeks followed by itraconazole for 10 weeks is based on one non-comparative study [1]. Amphotericin B has extremely limited availability, has significant side effects, needs to adminstered through a vein daily over 6 hours of infusion, and is prohibitively expensive in most areas of Asia. Itraconazole, on the other hand, is widely available in local pharmacies throughout Asia, can be given orally at a fraction of the price. Further, data from available case series suggest that itraconazole and amphotericin B have similar efficacies. We therefore propose to conduct a randomised, open-label, non-inferiority trial of the efficacy of itraconazole versus amphotericin B for penicilliosis. 440 adults from in and outpatient settings with culture-confirmed penicilliosis will be recruited, randomly allocated to either itraconazole or amphotericin B treatment, monitored daily in-hospital for 2 weeks, and at monthly intervals for a total of 6 months. Primary outcome is mortality at 2 weeks. Secondary outcomes include 6-month survival, clinical response, relapse, drug tolerability, and economic costs. Correlates of interests include admission prognostic factors, time-to-culture-sterilization, fungicidal activities, pharmacokinetic parameters, and serologic titres. These results will be available within five years and will either change or support current treatment guidelines for penicilliosis.</gtr:technicalSummary><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1540191</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Havard Medical School AIDS Inititive in Vietnam (HAIVN)</gtr:description><gtr:id>C28A89C9-4D12-49EE-84A1-EA9AF03060EC</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:partnerContribution>HAIVN runs the clinical trials and provides clinical samples and data for us to study HIV drug resistance development.</gtr:partnerContribution><gtr:piContribution>Collaborate in a randomized controlled trial to evaluate viral load monitoring to improve HIV treatment outcome in Vietnam</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>The epidemiology, diagnosis and treatment of penicilliosis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>33D8DEBB-4909-474B-BA6E-72FD77D75C04</gtr:id><gtr:impact>I gave a talk by video conference to HIV doctors in Vietnam about penicilliosis epidemiology, diagnosis and treatment

This is part of continue education for health care professionals in Vietnam</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>International Pilot Award</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>University of Washington</gtr:fundingOrg><gtr:fundingRef>NIH P30 AI 027757</gtr:fundingRef><gtr:id>7916B03F-031E-4C20-842E-B1A9ADF5B943</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>This project led to membership to the World Health Organization Guideline Development Group on Management of Advanced HIV</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>062614FC-1780-408B-ACF1-7214098EBD63</gtr:id><gtr:impact>The study provided the data on the mortality benefit of amphotericin B (compared to itraconazole) for treatment of talaromycosis. The study provided doctors in Vietnam with clinical trial evidence to use amphotericin B as initial treatment of talaromycosis in their clinical practice. The study team is meeting with Vietnam Ministry of Health later on this year to present the data and to advocate for improved procurement and access to amphotericin B therapy in Vietnam. The study will be cited in the 2017 updated WHO guidelines which will mention treatment options for talaromycosis.</gtr:impact><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>This study resulted in a largest prospectively collected data from more than 400 patients with culture-confirmed talaromycosis in the world to date. This rich dataset will allow multiple follow up evaluations of factors that impact patient outcomes as well as development of future models to predict outcomes in patients.</gtr:description><gtr:id>D7002D8A-656A-4CDF-AA13-DEF66DE30726</gtr:id><gtr:impact>This dataset will be shared with the research communities once our policy on data sharing is finalized.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Talaromycosis patient database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This project has enabled 3 microbiology laboratories in the provinces of Vietnam to improve the capacity to diagnose talaromycosis by microscopy and culture</gtr:description><gtr:id>D2B7F7E0-5A3B-4D63-A42D-2C2B8A4AAA04</gtr:id><gtr:impact>The provincial hospitals participated in the study are now able to make microbiology-confirmed talarmycosis. They were only making clinical diagnosis before participating in the study.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>This project has enabled 3 microbiology laboratories in the provinces of Vietnam to improve the capacity to diagnose talaromycosis by microscopy and culture</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The study enables the validation and optimization of a novel antigen detecting ELISA developed by our collaborators from Hong Kong for rapid and accurate diagnosis of talaromycosis</gtr:description><gtr:id>40AD7171-49C5-497F-BC78-295B53FFE761</gtr:id><gtr:impact>This method has allowed reduction of time to diagnosis of talaromycosis to on average 4 days, enable early treatment and improves patient outcomes.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Optimization of a serological assay for rapid diagnosis of talaromycosis</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This project improves the capacity of the 5 hospitals in Vietnam to conduct clinical trials</gtr:description><gtr:id>2B14C8E2-72FC-4782-A5DD-D84861232692</gtr:id><gtr:impact>The five hospitals participated in this study has improved their capacity to conduct high standard clinical research</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Good Clinical Practice training and training in the conduct of clinical trials</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This grant allows our group to develop a new real-time PCR assay that is able to detect pencilliosis within 5-6 hours in ~70% patients presenting without skin lesions, in whom conventional blood culture takes on average 5-7 days to diagnose the disease.</gtr:description><gtr:id>7226700B-1D0D-4D62-BECC-F5D884775901</gtr:id><gtr:impact>Not yet. We are submitting the paper and hope to continue to develop the assay for clinical use.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Developement of a new real-time PCR assay for rapid diagnosis of penicilliosis</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This funding has allowed us to develop a new simple assay to detect and quantify the fungal load in patient blood</gtr:description><gtr:id>FDE4A966-3482-40EA-93C8-31958EFFD917</gtr:id><gtr:impact>We are planning to publish this assay and hope that it can be used to monitor treatment response.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Development of a simple culture assay to quantify Penicillium marneffei in patient blood</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E9DFEBDF-A26C-4DD1-87B7-3768242B3677"><gtr:id>E9DFEBDF-A26C-4DD1-87B7-3768242B3677</gtr:id><gtr:title>Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam.</gtr:title><gtr:parentPublicationTitle>Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e2fdca735ca5352dcce9ebbfa672877"><gtr:id>1e2fdca735ca5352dcce9ebbfa672877</gtr:id><gtr:otherNames>Thao VP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0025-7974</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F1EEFEB9-60A7-4A3F-9238-52BD18124090"><gtr:id>F1EEFEB9-60A7-4A3F-9238-52BD18124090</gtr:id><gtr:title>Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/234971086e1080b9c2e8a03abc822bb7"><gtr:id>234971086e1080b9c2e8a03abc822bb7</gtr:id><gtr:otherNames>Le T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F63ED544-7CC2-4127-88DC-BAC6931652DE"><gtr:id>F63ED544-7CC2-4127-88DC-BAC6931652DE</gtr:id><gtr:title>CPE debate still unresolved</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/65beea7ceb2b9eee5ebc9704f3ead90e"><gtr:id>65beea7ceb2b9eee5ebc9704f3ead90e</gtr:id><gtr:otherNames>Justin Beardley, Thuy Le</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/804D8178-0B2E-42AF-99F5-5B83F1103D59"><gtr:id>804D8178-0B2E-42AF-99F5-5B83F1103D59</gtr:id><gtr:title>The decline of typhoid and the rise of non-typhoid salmonellae and fungal infections in a changing HIV landscape: bloodstream infection trends over 15 years in southern Vietnam.</gtr:title><gtr:parentPublicationTitle>Transactions of the Royal Society of Tropical Medicine and Hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/598c463aaba8eab10307c43bb1339d04"><gtr:id>598c463aaba8eab10307c43bb1339d04</gtr:id><gtr:otherNames>Nga TV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0035-9203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/05B08CF0-BAA4-4D1C-82AB-B4294C95E8E9"><gtr:id>05B08CF0-BAA4-4D1C-82AB-B4294C95E8E9</gtr:id><gtr:title>Environmental predictors and incubation period of AIDS-associated penicillium marneffei infection in Ho Chi Minh City, Vietnam.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/55f031503605171dcbf9aacfdc64f6d3"><gtr:id>55f031503605171dcbf9aacfdc64f6d3</gtr:id><gtr:otherNames>Bulterys PL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/49A3BB99-21F2-471B-A64A-E6F490793EB0"><gtr:id>49A3BB99-21F2-471B-A64A-E6F490793EB0</gtr:id><gtr:title>High prevalence of PI resistance in patients failing second-line ART in Vietnam.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e2fdca735ca5352dcce9ebbfa672877"><gtr:id>1e2fdca735ca5352dcce9ebbfa672877</gtr:id><gtr:otherNames>Thao VP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/94275AEB-2D29-4024-A8D7-D92F9385CB99"><gtr:id>94275AEB-2D29-4024-A8D7-D92F9385CB99</gtr:id><gtr:title>Looking for fungi in all the right places: screening for cryptococcal disease and other AIDS-related mycoses among patients with advanced HIV disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/03cd336163c85a32ca607e53846090b2"><gtr:id>03cd336163c85a32ca607e53846090b2</gtr:id><gtr:otherNames>Greene G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/756C87CB-E238-426C-85F1-4953DE97C5E1"><gtr:id>756C87CB-E238-426C-85F1-4953DE97C5E1</gtr:id><gtr:title>Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/234971086e1080b9c2e8a03abc822bb7"><gtr:id>234971086e1080b9c2e8a03abc822bb7</gtr:id><gtr:otherNames>Le T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A96A55EE-6F4C-4BC9-8E94-88517ADCC349"><gtr:id>A96A55EE-6F4C-4BC9-8E94-88517ADCC349</gtr:id><gtr:title>Diagnosing Rhodococcus equi infections in a setting where tuberculosis is highly endemic: a double challenge.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/234971086e1080b9c2e8a03abc822bb7"><gtr:id>234971086e1080b9c2e8a03abc822bb7</gtr:id><gtr:otherNames>Le T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/22062593-9B09-486A-AFCB-08DA87F1EC6A"><gtr:id>22062593-9B09-486A-AFCB-08DA87F1EC6A</gtr:id><gtr:title>Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c4724e2a5c7d3379ef01fabff0b7f22"><gtr:id>6c4724e2a5c7d3379ef01fabff0b7f22</gtr:id><gtr:otherNames>Beardsley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB03D489-EC56-4A00-A63D-075AD2E440E6"><gtr:id>DB03D489-EC56-4A00-A63D-075AD2E440E6</gtr:id><gtr:title>Invasive Non-typhoidal Salmonella Infections in Asia: Clinical Observations, Disease Outcome and Dominant Serovars from an Infectious Disease Hospital in Vietnam.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/60109520ccb49ee4c01bf26bf8c50c85"><gtr:id>60109520ccb49ee4c01bf26bf8c50c85</gtr:id><gtr:otherNames>Phu Huong Lan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB177A17-68E2-46CF-A474-899D8C9E3CF8"><gtr:id>BB177A17-68E2-46CF-A474-899D8C9E3CF8</gtr:id><gtr:title>Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of Talaromyces marneffei MP1 gene in human plasma.</gtr:title><gtr:parentPublicationTitle>Mycoses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e60e4326d9be7959ec47f52aa175cd80"><gtr:id>e60e4326d9be7959ec47f52aa175cd80</gtr:id><gtr:otherNames>Hien HT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0933-7407</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/085F6817-A625-45C6-8A1B-77A57CDD15CC"><gtr:id>085F6817-A625-45C6-8A1B-77A57CDD15CC</gtr:id><gtr:title>Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam.</gtr:title><gtr:parentPublicationTitle>AIDS research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4639e8ef34a2b28d53c1c06374e34c12"><gtr:id>4639e8ef34a2b28d53c1c06374e34c12</gtr:id><gtr:otherNames>Larsson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-6405</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CCE9904B-EE09-442A-95DF-1AFA1A5ABFF2"><gtr:id>CCE9904B-EE09-442A-95DF-1AFA1A5ABFF2</gtr:id><gtr:title>HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e2fdca735ca5352dcce9ebbfa672877"><gtr:id>1e2fdca735ca5352dcce9ebbfa672877</gtr:id><gtr:otherNames>Thao VP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100682</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>